Opportunities for improvement in the cardiovascular care of patients with end-stage renal disease

Advances in Chronic Kidney Disease

Volumn 11, Issue 3, 2004, Pages 294-303

  McCullough, Peter A ^a,b  

^a Nutr   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

acute coronary syndromes; atherosclerosis; Cardiovascular disease; end stage renal disease; heart failure; sudden death

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; EPTIFIBATIDE; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; IRON; LEPIRUDIN; LOOP DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; MILRINONE; NESIRITIDE; NICOTINIC ACID; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; STATIN; TICLOPIDINE; TIROFIBAN;

ANEMIA; ATHEROSCLEROSIS; BLEEDING; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEFIBRILLATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DYSLIPIDEMIA; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; KIDNEY FAILURE; MORBIDITY; MORTALITY; MYOCARDIAL DISEASE; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING CESSATION; SUDDEN DEATH;

EID: 3242694312     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.arrt.2004.04.009     Document Type: Article

References (61)

1. McCullough P.A. Cardiorenal risk An important clinical intersection. Rev Cardiovasc Med. 3:2002;71-76
2. Adler A.I., Stevens R.J., Manley S.E., et al. Development and progression of nephropathy in type 2 diabetes the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63:2003;225-232
3. Agarwal R., Nissenson A.R., Batlle D., et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 115:2003;291-297
4. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 289:2003;2560-2572
5. Vlahakos D.V., Hahalis G., Vassilakos P., et al. Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol. 8:1997;1764-1770
6. Toto R. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med. 161:2001;1492-1499
7. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 345:2001;861-869
8. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345:2001;851-860
9. Parving H.H., Lehnert H., Brochner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 345:2001;870-878
10. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) A randomised trial against atenolol. Lancet. 359:2002;995-1003
11. Mann J.F., Gerstein H.C., Pogue J., et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril The HOPE randomized trial. Ann Intern Med. 134:2001;629-636
12. Hampl H., Sternberg C., Berweck S., et al. Regression of left ventricular hypertrophy in hemodialysis patients is possible. Clin Nephrol. 58:(suppl 1):2002;S73-S96
13. Agodoa L.Y., Appel L., Bakris G.L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis A randomized controlled trial. JAMA. 285:2001;2719-2728
14. Li P.K., Chow K.M., Wong T.Y., et al. Effects of an angiotensin- converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis A randomized, controlled study. Ann Intern Med. 139:2003;105-112
15. McCullough P.A., Sandberg K.R., Yee J., et al. Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst. 3:2002;188-191
16. Bakris G.L. Role for beta-blockers in the management of diabetic kidney disease. Am J Hypertens. 16:(9 pt 2 suppl):2003;7S-12S
17. Cice G., Ferrara L., D'Andrea A., et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy A prospective, placebo-controlled trial. J Am Coll Cardiol. 41:2003;1438-1444
18. McCullough P.A., Sandberg K.R., Borzak S., et al. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J. 144:2002;226-232
19. Porter G.A., Norton T.L., Lindsley J., et al. Relationship between elevated serum troponin values in end-stage renal disease patients and abnormal isotopic cardiac scans following stress. Ren Fail. 25:2003;55-65
20. Buemi M., Senatore M., Corica F., et al. Statins and progressive renal disease. Med Res Rev. 22:2002;76-84
21. Oda H., Keane W.F. Recent advances in statins and the kidney. Kidney Int. 71:(suppl):1999;S2-S5
22. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
23. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 26:(suppl 1):2003;S33-S50
24. Biesenbach G., Zazgornik J. Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. Diabetes Care. 19:1996;625-628
25. Benowitz N.L. Pharmacology of nicotine addiction and therapeutics. Annu Rev Pharmacol Toxicol. 36:1996;597-613
26. Michael Pittilo R. Cigarette smoking, endothelial injury and cardiovascular disease. Int J Exp Pathol. 81:2000;219-230
27. Wilson K., Gibson N., Willan A., et al. Effect of smoking cessation on mortality after myocardial infarction Meta-analysis of cohort studies. Arch Intern Med. 160:2000;939-944
28. Weisman S.M., Graham D.Y. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 162:2002;2197-2202
29. Winchester J.F. Therapeutic uses of aspirin in renal diseases. Am J Kidney Dis. 28:(suppl 1):1996;S20-S23
30. Kaufman J.S., Fiore L., Hasbargen J.A., et al. A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. J Thromb Thrombolysis. 10:2000;127-131
31. van Guldener C., Stam F., Stehouwer C.D. Homocysteine metabolism in renal failure. Kidney Int. 78:(suppl):2001;S234-S237
32. Moustapha A., Naso A., Nahlawi M., et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 97:1998;138-141
33. Shemin D., Bostom A.G., Selhub J. Treatment of hyperhomocysteinemia in end-stage renal disease. Am J Kidney Dis. 38:(suppl 1):2001;S91-S94
34. Koenig W. Update on C-reactive protein as a risk marker in cardiovascular disease. Kidney Int. 84:(suppl):2003;S58-S61
35. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979. Erratum in: N Engl J Med 337:356, 1997
36. Herzog C.A., Ma J.Z., Collins A.J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 339:1998;799-805
37. Shlipak M.G. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med. 138:2003;917-924
38. McCullough P.A. Acute coronary syndromes in patients with renal failure. Curr Cardiol Rep. 5:2003;266-270
39. Sica D. The implications of renal impairment among patients undergoing percutaneous coronary intervention. J Invasive Cardiol. 14:(suppl B):2002;30B-37B
40. Schreiber B.D. Congestive heart failure in patients with chronic kidney disease and on dialysis. Am J Med Sci. 325:2003;179-193
41. McCullough P.A., Duc P., Omland T., et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure an analysis from the breathing not properly multinational study. Am J Kidney Dis. 41:2003;571-579
42. McCullough P.A., Sandberg K.R. B-type natriuretic Peptide and renal disease. Heart Fail Rev. 8:2003;355-358
43. Al-Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 38:2001;955-962
44. Mancini D.M., Katz S.D., Lang C.C., et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 107:2003;294-299
45. Shlipak M.G. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med. 138:2003;917-924
46. Schoolwerth A.C., Sica D.A., Ballermann B.J., et al. Renal considerations in angiotensin converting enzyme inhibitor therapy A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 104:2001;1985-1991
47. Keating G.M., Goa K.L. Nesiritide A review of its use in acute decompensated heart failure. Drugs. 63:2003;47-70
48. Tamura K., Tsuji H., Nishiue T., et al. Determinants of ventricular arrhythmias in hemodialysis patients Evaluation of the effects of arrhythmogenic substrate and autonomic imbalance. Am J Nephrol. 18:1998;280-284
49. De Lima J.J., Vieira M.L., Lopes H.F., et al. Blood pressure and the risk of complex arrthymia in renal insufficiency Hemodialysis and renal transplant patients. Am J Hypertens. 12:1999;204-208
50. Herzog C.A. Cardiac arrest in dialysis patients Approaches to alter an abysmal outcome. Kidney Int. 84:(suppl):2003;S197-S200
51. The Antiarrythmics versus Implantable Defibrillators Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillator in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 337:1997;1576-1583
52. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 346:2002;877-883
53. Kocheril A.G. Arrhythmia issues in patients with renal disease. Semin Nephrol. 21:(1):2001;57-65
54. London G.M. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant. 17:(suppl 1):2002;29-36
55. Converse R.L., Jacobsen T.N., Toto R.D., et al. Sympathetic over activity in the patients with chronic renal failure. N Engl J Med. 327:1992;1912-1918
56. Amann K., Breitbach M., Ritz E., et al. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol. 9:1998;1018-1022
57. Narula A.S., Jha V., Bali H.K., et al. Cardiac arrhythmias and silent myocardial ischemia during hemodialysis. Ren Fail. 22:2000;355-368
58. Cupisti A., Galetta F., Caprioli R., et al. Potassium removal increases the Q-Tc interval dispersion during hemodialysis. Nephron. 82:1999;122-126
59. Wase A., Basit A., Nazir R. Does chronic renal insufficiency raise defibrillation threshold? Pacing Clin Electrophysiol. 25:(4 pt II):2002;594
60. Gregoratos G., Abrams J., Epstein A.E., et al. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation. 106:2002;2145-2161
61. McCullough P.A. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol. 41:2003;725-728